Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eslicarbazepine acetate - Bial

Drug Profile

Eslicarbazepine acetate - Bial

Alternative Names: Aptiom; BIA 2-093; ESL; Eslicarbazepine; Exalief; SEP-0002093; SEP-2093; Stedesa; Zebinix

Latest Information Update: 30 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bial
  • Developer BIAL; Eisai Co Ltd; Sunovion Pharmaceuticals; Whanin Pharmaceutical
  • Class Acetates; Amides; Analgesics; Antiepileptic drugs; Antimigraines; Dibenzazepines; Esters; Mood stabilisers; Small molecules
  • Mechanism of Action Sodium channel antagonists; T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase II Epilepsy; Migraine
  • Discontinued Bipolar disorders; Fibromyalgia; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 22 Oct 2019 Pooled efficacy data from the phase III 093-045 and 093-046 trials in Partial seizures (monotherapy) presented at the 71th Annual Meeting of the American Academy of Neurology (AAN-2019)
  • 22 Aug 2019 Phase-I clinical trials in Partial epilepsies (In volunteers) in South Korea (PO) (NCT04095182)
  • 24 Apr 2019 Phase-II clinical trials in Epilepsy (In adults, Prevention) in Spain (PO) (EudraCT2018-002747-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top